63 related articles for article (PubMed ID: 26443812)
1. The usage of a three-compartment model to investigate the metabolic differences between hepatic reductase null and wild-type mice.
Hill L; Chaplain MAJ; Wolf R; Kapelyukh Y
Math Med Biol; 2017 Mar; 34(1):1-13. PubMed ID: 26443812
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the metabolism of midazolam in C57BL/6J and hepatic reductase null (HRN) mice.
Grimsley A; Foster A; Gallagher R; Hutchison M; Lundqvist A; Pickup K; Wilson ID; Samuelsson K
Biochem Pharmacol; 2014 Dec; 92(4):701-11. PubMed ID: 25450676
[TBL] [Abstract][Full Text] [Related]
3. Role of hepatic cytochrome p450s in the pharmacokinetics and toxicity of cyclophosphamide: studies with the hepatic cytochrome p450 reductase null mouse.
Pass GJ; Carrie D; Boylan M; Lorimore S; Wright E; Houston B; Henderson CJ; Wolf CR
Cancer Res; 2005 May; 65(10):4211-7. PubMed ID: 15899812
[TBL] [Abstract][Full Text] [Related]
4. Metabolic activation of benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with detoxification in vivo: experiments with hepatic cytochrome P450 reductase null mice.
Arlt VM; Stiborová M; Henderson CJ; Thiemann M; Frei E; Aimová D; Singh R; Gamboa da Costa G; Schmitz OJ; Farmer PB; Wolf CR; Phillips DH
Carcinogenesis; 2008 Mar; 29(3):656-65. PubMed ID: 18204078
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the hepatic CYP reductase null mouse model and its potential application in drug discovery.
Boggs JW; Hop CE; McNamara E; Deng Y; Messick K; West K; Choo EF
Mol Pharm; 2014 Mar; 11(3):1062-8. PubMed ID: 24450768
[TBL] [Abstract][Full Text] [Related]
6. Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse.
Stiborová M; Arlt VM; Henderson CJ; Wolf CR; Kotrbová V; Moserová M; Hudecek J; Phillips DH; Frei E
Toxicol Appl Pharmacol; 2008 Feb; 226(3):318-27. PubMed ID: 17976674
[TBL] [Abstract][Full Text] [Related]
7. Role of cytochromes P450 1A1/2 in detoxication and activation of carcinogenic aristolochic acid I: studies with the hepatic NADPH:cytochrome P450 reductase null (HRN) mouse model.
Levová K; Moserová M; Kotrbová V; Sulc M; Henderson CJ; Wolf CR; Phillips DH; Frei E; Schmeiser HH; Mares J; Arlt VM; Stiborová M
Toxicol Sci; 2011 May; 121(1):43-56. PubMed ID: 21362632
[TBL] [Abstract][Full Text] [Related]
8. Evidence that cytochrome b5 and cytochrome b5 reductase can act as sole electron donors to the hepatic cytochrome P450 system.
Henderson CJ; McLaughlin LA; Wolf CR
Mol Pharmacol; 2013 Jun; 83(6):1209-17. PubMed ID: 23530090
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase.
Henderson CJ; Otto DM; Carrie D; Magnuson MA; McLaren AW; Rosewell I; Wolf CR
J Biol Chem; 2003 Apr; 278(15):13480-6. PubMed ID: 12566435
[TBL] [Abstract][Full Text] [Related]
10. The application of hepatic P450 reductase null gpt delta mice in studying the role of hepatic P450 in genotoxic carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mutagenesis.
Luan Y; Xing G; Qi X; Wu M; Li C; Yao J; Gong L; Nohmi T; Gu J; Zhou W; Zheng S; Ren J
Arch Toxicol; 2012 Nov; 86(11):1753-61. PubMed ID: 22710403
[TBL] [Abstract][Full Text] [Related]
11. Transgenic mice with a hypomorphic NADPH-cytochrome P450 reductase gene: effects on development, reproduction, and microsomal cytochrome P450.
Wu L; Gu J; Cui H; Zhang QY; Behr M; Fang C; Weng Y; Kluetzman K; Swiatek PJ; Yang W; Kaminsky L; Ding X
J Pharmacol Exp Ther; 2005 Jan; 312(1):35-43. PubMed ID: 15328377
[TBL] [Abstract][Full Text] [Related]
12. The hepatic cytochrome P450 reductase null mouse as a tool to identify a successful candidate entity.
Henderson CJ; Pass GJ; Wolf CR
Toxicol Lett; 2006 Mar; 162(1):111-7. PubMed ID: 16343823
[TBL] [Abstract][Full Text] [Related]
13. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes.
Li J; Zhao M; He P; Hidalgo M; Baker SD
Clin Cancer Res; 2007 Jun; 13(12):3731-7. PubMed ID: 17575239
[TBL] [Abstract][Full Text] [Related]
14. Relationship between hepatic phenotype and changes in gene expression in cytochrome P450 reductase (POR) null mice.
Wang XJ; Chamberlain M; Vassieva O; Henderson CJ; Wolf CR
Biochem J; 2005 Jun; 388(Pt 3):857-67. PubMed ID: 15717863
[TBL] [Abstract][Full Text] [Related]
15. Determination of the role of target tissue metabolism in lung carcinogenesis using conditional cytochrome P450 reductase-null mice.
Weng Y; Fang C; Turesky RJ; Behr M; Kaminsky LS; Ding X
Cancer Res; 2007 Aug; 67(16):7825-32. PubMed ID: 17699788
[TBL] [Abstract][Full Text] [Related]
16. UHPLC-MS-Based Lipidomic and Metabonomic Investigation of the Metabolic Phenotypes of Wild Type and Hepatic CYP Reductase Null (HRN) Mice.
Gray N; Gethings LA; Plumb RS; Wilson ID
J Pharm Biomed Anal; 2020 Jul; 186():113318. PubMed ID: 32380354
[TBL] [Abstract][Full Text] [Related]
17. A mouse model with liver-specific deletion and global suppression of the NADPH-cytochrome P450 reductase gene: characterization and utility for in vivo studies of cyclophosphamide disposition.
Gu J; Chen CS; Wei Y; Fang C; Xie F; Kannan K; Yang W; Waxman DJ; Ding X
J Pharmacol Exp Ther; 2007 Apr; 321(1):9-17. PubMed ID: 17218484
[TBL] [Abstract][Full Text] [Related]
18. Conditional deletion of cytochrome P450 oxidoreductase in the liver and gastrointestinal tract: a new model for studying the functions of the P450 system.
Finn RD; McLaren AW; Carrie D; Henderson CJ; Wolf CR
J Pharmacol Exp Ther; 2007 Jul; 322(1):40-7. PubMed ID: 17435107
[TBL] [Abstract][Full Text] [Related]
19. Reconstitution premixes for assays using purified recombinant human cytochrome P450, NADPH-cytochrome P450 reductase, and cytochrome b5.
Shaw PM; Hosea NA; Thompson DV; Lenius JM; Guengerich FP
Arch Biochem Biophys; 1997 Dec; 348(1):107-15. PubMed ID: 9390180
[TBL] [Abstract][Full Text] [Related]
20. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]